Table 2.
Comparison of cohorts of patients concomitantly receiving CDK4/6 inhibitor and radiation therapy.
| CDK4/6 inhibitor | Patients | Number of irradiated sites | Location metastasis | LR | RT suspension required | CDKi suspension required | Grade 2 non-haematologic toxicities | Grade ≥ 2 haematologic toxicities | |
|---|---|---|---|---|---|---|---|---|---|
| Hans et al.3 (6) | Palbociclib | 5 | 5 | Bone (4), visceral (1) | 0 | 0 | 0 | 0 | 5 (100%) |
| Meattini et al.4 (11) | Ribociclib | 5 | 8 | Bone (5) and visceral (3) | 0 | 0 | 2 (40%) | 2 (25%) | 1 (20%) |
| Kawamoto et al.8 (7) | Palbociclib | 1 | 1 | Bone (1) | 0 | 1 (100%) | 1 (100%) | 1 (100%) | na |
| Kalash et al.9 (8) | Palbociclib | 3 | 3 | Lung (3) | 0 | 3 | 3 (100%) | 3 (100%) | na |
| Chowdhary et al.5 (12) | Palbociclib | 16 | 23 | Bone (18), brain (4) and visceral (1) | 0 | 0 | 0 | 0 | na |
| Messer et al.10 (15) | Palbociclib | 1 | 1 | 0 | 1 (L4) | 1 (100%) | 1 (100%) | 1 (100%) | na |
| Figura et al.6 (13) | Palbociclib and abemaciclib | 15 | 42 | Brain (42) | 0 | 0 | 0 | 2 (5%) | na |
| Ippolito et al.7 (14) | Palbociclib and ribociclib | 16 | 24 | Bone (23) | 1 (IMC) | 2 (12%) | 1 (6%) | 1 (4%) | 31% |
| Our study (2019) | Palbociclib | 30 | 35 | Bone (24) and brain (2) | 9 | 2 (6%) | 3 (10%) | 3 (8%) | 8 (26%) |
LR locoregional, IMC intermammary chain, CDKi CDK inhibitor.